This article is more than 5 years old. Information may no longer be current.

Sight Sciences receives IDE approval to initiate clinical trial of ab interno canaloplasty system vs. SLT

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Sight Sciences received full investigational device exemption approval from the FDA to initiate a clinical trial comparing ab interno canaloplasty and selective laser trabeculoplasty, according to a press release.

The multicenter, prospective, randomized, controlled clinical trial will evaluate the safety and efficacy of the Visco360 viscosurgical system in reducing IOP in patients with primary open-angle glaucoma vs. SLT.

“We believe there is a huge unmet need for an effective ab interno glaucoma procedure that is not performed in conjunction with cataract removal, and we look forward to working with all of our clinical partners in the execution of this large, robust FDA clinical study,” Paul Badawi, co-founder and CEO of Sight Sciences, said in the release.